Literature DB >> 20821796

Drugs for hepatitis C: unlocking a new mechanism of action.

Thomas W Bell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20821796     DOI： 10.1002/cmdc.201000334

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  3 in total

1.  Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

Authors:  Simon Giroux; Jinwang Xu; T Jagadeeswar Reddy; Mark Morris; Kevin M Cottrell; Caroline Cadilhac; James A Henderson; Oliver Nicolas; Darius Bilimoria; Francois Denis; Nagraj Mani; Nigel Ewing; Rebecca Shawgo; Lucille L'Heureux; Subajini Selliah; Laval Chan; Nathalie Chauret; Francoise Berlioz-Seux; Mark N Namchuk; Anne-Laure Grillot; Youssef L Bennani; Sanjoy K Das; John P Maxwell
Journal:  ACS Med Chem Lett       Date:  2013-01-27       Impact factor: 4.345

Review 2.  HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.

Authors:  Kazuaki Chayama; C Nelson Hayes
Journal:  Viruses       Date:  2015-10-13       Impact factor: 5.048

3.  Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.

Authors:  Youngsu You; Hee Sun Kim; Jung Woo Park; Gyochang Keum; Sung Key Jang; B Moon Kim
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.